|
|
Post by compound26 on Jun 29, 2017 16:24:50 GMT -5
I was discussing with someone else on this board earlier today. I think the one-drop subscription model could work very well with PWDs who just want to use Afrezza for corrections.
So you can have someone at VDEX (who is willing to write Afrezza scripts) writing scripts remotely and then ship to those PWDs Afrezza up to a certain number of boxes per month (or per year if they pay the annual subscription fee in our payment).
You can use a credit system to simplify things. So for example, if they pay an annual subscription fee of $1,200 (that translates to $100 a month), you can convert that into 12 or 24 credits. Each time they used up their inventory of Afrezza at hand and need a new shipment of Afrezza, you will apply 1, 2 or 3 credits depending on how many units the shipment contains.
So in essence, this works very much like the subscription service I get from Audible.com (now part of Amazon).
Now if a PWD used up his/her 12/24 credits in less than 12 months, he/she can then either pay cash to order Afrezza at a discounted price (say getting a 30% discount by being a subscription service member) or elects to renew his/her annual membership earlier (less than 12 months) and get another 12/24 credits.
I think the above subscription model could work very well with PWDs who just want to use Afrezza for corrections because their usage of Afrezza will be more limited and therefore a relatively low subscription price (say $1,200 a year (that translates to $100 a month)) can work with both such PWDs and Mannkind.
Of course, for PWDs who need more Afrezza, we can have a tiered subscription services. E.g., $100/month limited to one box per month, $150/month limited to two boxes per month, $200/month limited to three boxes per month, etc. [The numbers are just for illustration purposes as I have not crunched the numbers yet.]
Just something for your consideration.
What do you all think?
|
|
|
|
Post by madog365 on Jun 29, 2017 16:52:56 GMT -5
|
|
|
|
Post by lakers on Jun 30, 2017 0:19:01 GMT -5
The ultra-ultra-fast absorption and action of Afrezza lend themselves perfectly to delivery of “rescue” doses of insulin in the face of unexpected hyperglycemia. The nonin- vasive, convenient inhalation device, coupled with the lack of need for constant refrigeration, add to the appeal of Afrezza for this use. www.mannkindcorp.com/assets/Muchmore-JDiabSciTech-2017.pdf |
|
|
|
Post by straightly on Jun 30, 2017 1:16:18 GMT -5
The ultra-ultra-fast absorption and action of Afrezza lend themselves perfectly to delivery of “rescue” doses of insulin in the face of unexpected hyperglycemia. The nonin- vasive, convenient inhalation device, coupled with the lack of need for constant refrigeration, add to the appeal of Afrezza for this use. www.mannkindcorp.com/assets/Muchmore-JDiabSciTech-2017.pdfThis reads like a very exciting publication. Shouldn't we put this in its own thread? "The need for faster insulin: problem solved?" with a resounding YES answer. Here is hope that the words get out faster than our money runs out. |
|
|
|
Post by wgreystone on Jun 30, 2017 12:38:45 GMT -5
I was discussing with someone else on this board earlier today. I think the one-drop subscription model could work very well with PWDs who just want to use Afrezza for corrections. So you can have someone at VDEX (who is willing to write Afrezza scripts) writing scripts remotely and then ship to those PWDs Afrezza up to a certain number of boxes per month (or per year if they pay the annual subscription fee in our payment). You can use a credit system to simplify things. So for example, if they pay an annual subscription fee of $1,200 (that translates to $100 a month), you can convert that into 12 or 24 credits. Each time they used up their inventory of Afrezza at hand and need a new shipment of Afrezza, you will apply 1, 2 or 3 credits depending on how many units the shipment contains. So in essence, this works very much like the subscription service I get from Audible.com (now part of Amazon). Now if a PWD used up his/her 12/24 credits in less than 12 months, he/she can then either pay cash to order Afrezza at a discounted price (say getting a 30% discount by being a subscription service member) or elects to renew his/her annual membership earlier (less than 12 months) and get another 12/24 credits. I think the above subscription model could work very well with PWDs who just want to use Afrezza for corrections because their usage of Afrezza will be more limited and therefore a relatively low subscription price (say $1,200 a year (that translates to $100 a month)) can work with both such PWDs and Mannkind. Of course, for PWDs who need more Afrezza, we can have a tiered subscription services. E.g., $100/month limited to one box per month, $150/month limited to two boxes per month, $200/month limited to three boxes per month, etc. [The numbers are just for illustration purposes as I have not crunched the numbers yet.] Just something for your consideration. What do you all think? This is the model I thought that could work as the first step of collaboration between OneDrop and Mannkind. OneDrop could hire a team of physicians to check patients' BG history (which OneDrop should already have for its subscription patients) and order necessary tests (FEV,etc), and then write prescriptions. |
|
|
|
Post by lennymnkd on Jun 30, 2017 14:26:42 GMT -5
Use the emergency doseing like an epi pen !
|
|
|
|
Post by madog365 on Jul 20, 2017 10:44:25 GMT -5
|
|
|
|
Post by matt on Jul 20, 2017 11:22:56 GMT -5
So you can have someone at VDEX (who is willing to write Afrezza scripts) writing scripts remotely and then ship to those PWDs Afrezza up to a certain number of boxes per month (or per year if they pay the annual subscription fee in our payment). Just something for your consideration. What do you all think? I don't think this is feasible because most physicians won't write a script for a patient they haven't seen in person, and that includes refills if the patient has not visited their office in the past year (six months in some cases). I don't know if that is state law in some places, a provision of their medical malpractice policy, or just prudent medical practice, but given the complexity of diabetes and the associated comorbid conditions, I don't see a physician treating a new patient by remote control without the benefit of lab work (which also requires a physician's order in most cases). If OneDrop were licensed as a pharmacy, they could certainly ship the drug along with the test strips for a negotiated subscription price, but there would still need to be a willing physician to write that script. |
|
|
|
Post by n8 on Jul 20, 2017 13:46:31 GMT -5
Going OVER THE COUNTER so prescriptions will be irrelevant.
|
|
|
|
Post by dreamboatcruise on Jul 20, 2017 14:01:49 GMT -5
Going OVER THE COUNTER so prescriptions will be irrelevant. Yes, that might be a possibility... years and years from now after the long term safety trial is done. It'll be exciting to think about the possibility for the next 5 years. Please remind us at least once a year so we don't lose track of it. |
|
|
|
Post by sportsrancho on Jul 20, 2017 14:47:20 GMT -5
I don't know about the One Drop stuff.... but you can call Vedex and get a script now. ( Because it's a clinic )
Other doctors do want you to be their patient before they will hand out scripts.
|
|
|
|
Post by dreamboatcruise on Jul 20, 2017 15:41:56 GMT -5
I don't know about the One Drop stuff.... but you can call Vedex and get a script now. ( Because it's a clinic ) Other doctors do want you to be their patient before they will hand out scripts. That's very helpful. Do you know if they are, or are planning to do advertising? There is an issue that many insurance plans (most HMOs) don't cover prescriptions if it is a doctor that isn't your assigned PCP or from a authorized referral (or provider network for PPOs). But there would be some insurance that would cover it and some people that could afford out of pocket for Afrezza. Wish we had some more news from VDex... how many patients on Afrezza? What is their drop out rate for Afrezza use (presumably much lower than what had historically been the case)? Are they collecting A1c and/or time in range data... can they use that in marketing (I think as a clinic they can) and do they plan to? Mannkind can't use data from sources such as VDex for marketing Afrezza to patients, but they sure could use it in marketing aimed at investors and partners. I am at the same time hopeful that such data will be revealed soon, but worried as to why it has not already been. So goes my entire experience as MNKD investor... hopefull but worried. |
|
|
|
Post by sportsrancho on Jul 20, 2017 16:19:24 GMT -5
I don't know about the One Drop stuff.... but you can call Vedex and get a script now. ( Because it's a clinic ) Other doctors do want you to be their patient before they will hand out scripts. That's very helpful. Do you know if they are, or are planning to do advertising? There is an issue that many insurance plans (most HMOs) don't cover prescriptions if it is a doctor that isn't your assigned PCP or from a authorized referral (or provider network for PPOs). But there would be some insurance that would cover it and some people that could afford out of pocket for Afrezza. Wish we had some more news from VDex... how many patients on Afrezza? What is their drop out rate for Afrezza use (presumably much lower than what had historically been the case)? Are they collecting A1c and/or time in range data... can they use that in marketing (I think as a clinic they can) and do they plan to? Mannkind can't use data from sources such as VDex for marketing Afrezza to patients, but they sure could use it in marketing aimed at investors and partners. I am at the same time hopeful that such data will be revealed soon, but worried as to why it has not already been. So goes my entire experience as MNKD investor... hopefull but worried. Yes on planning to advertise. ( Having to get their IT ducks on a row ) But I doubt they will give out their business plan. It's not their MO:-) Someone posted what they were doing per month and I can't find the post.. |
|
|
|
Post by dreamboatcruise on Jul 20, 2017 16:31:36 GMT -5
That's very helpful. Do you know if they are, or are planning to do advertising? There is an issue that many insurance plans (most HMOs) don't cover prescriptions if it is a doctor that isn't your assigned PCP or from a authorized referral (or provider network for PPOs). But there would be some insurance that would cover it and some people that could afford out of pocket for Afrezza. Wish we had some more news from VDex... how many patients on Afrezza? What is their drop out rate for Afrezza use (presumably much lower than what had historically been the case)? Are they collecting A1c and/or time in range data... can they use that in marketing (I think as a clinic they can) and do they plan to? Mannkind can't use data from sources such as VDex for marketing Afrezza to patients, but they sure could use it in marketing aimed at investors and partners. I am at the same time hopeful that such data will be revealed soon, but worried as to why it has not already been. So goes my entire experience as MNKD investor... hopefull but worried. Yes on planning to advertise. ( Having to get their IT ducks on a row ) But I doubt they will give out their business plan. It's not their MO:-) Someone posted what they were doing per month and I can't find the post.. I can understand business plan not being released, but prior performance is something different. Look at OneDrop... they certainly are touting their success. I've run a couple of startup companies and followed many others. It's hard to think of any valid reason they wouldn't be talking about success, if indeed the numbers look good. In particular in this case VDex would seem to have a strong motivation to help strengthen MNKD to assure the survival of Afrezza... and get to the point where supply chain issues don't affect patients. |
|
|
|
Post by me on Jul 20, 2017 17:00:40 GMT -5
I don't know about the One Drop stuff.... but you can call Vedex and get a script now. ( Because it's a clinic ) Other doctors do want you to be their patient before they will hand out scripts. That's very helpful. Do you know if they are, or are planning to do advertising? There is an issue that many insurance plans (most HMOs) don't cover prescriptions if it is a doctor that isn't your assigned PCP or from a authorized referral (or provider network for PPOs). Are you sure about this??? I've been in the employee benefit business for 30 years, sold to some of the largest employers for two large health insurance companies, served on two state health insurance and managed care regulatory bodies, been a CFO for a billion dollars of large group insurance revenues, filed numerous insurance and managed care rates and plans with three different insurance departments, started an HMO, co-founded a managed dental company, worked as a large group employee benefit consultant for an insurance agency and founded a prescription benefit administrator. There are some plans that limit the pharmacies one may use to get a benefit, but I don't think I've ever seen a contract that defines an eligible prescription as having to be written by a participating physician. This would create an administrative nightmare between the plan, its PBM and the pharmacy network. I'm not saying this isn't the case, but I've never seen it. I'd be interested in knowing what plans do this. Are there still staff model HMOs out there (it's been 20 years since I started my HMO), and might they have this limitation? |
|
